PI3.F Gubra A/S

Healthcare Biotechnology Frankfurt Exchange
39.80 EUR
Close of Nov 12, 2026
37.18 73.15
Market cap
EUR 653M
P/E
-
P/B
4.69x
ROE
147.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is PI3.F undervalued?

Graham number

The Graham number of Gubra A/S cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gubra A/S fundamental analysis

No fundamental analysis for Gubra A/S yet.

Gubra A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gubra A/S

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharma…

Full company profile